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Abstract
Background: Arsenic trioxide has been established as a first-line agent for treating acute promyelocytic leukemia. 
Experimental data suggest that arsenic trioxide also can have a potential use as chemotherapeutic agent for other 
malignancies. The precise mechanisms of action of arsenic trioxide have though not been elucidated. As the role of Bcl-
2 in arsenic trioxide-mediated cell apoptosis and conformation change of Bcl-2 in response to arsenic trioxide 
treatment has not been studied. The aim of the present study was to determine whether conformation change of Bcl-
2 is involved in the action of arsenic trioxide.
Methods: Human gastric cancer SGC7901 cells were exposed to different concentrations of arsenic trioxide. 
Proliferation was measured by using the Kit-8 cell counting assay. Analysis of nuclear morphology was observed by 
DAPI staining. The apoptosis rates of cells treated with arsenic trioxide were analyzed by flow cytometry using Annexin 
V-FITC staining. The conformation change of Bcl-2 and Bax activation were detected by immunostaining and Western 
blot analysis. Total expression of Bcl-2 and Bax were examined by Western blot analysis.
Results: Arsenic trioxide inhibited the growth of human gastric cancer SGC7901 cells and induced apoptosis. There 
were two Bcl-2 phenotypes coexisting in SGC7901 cells and the Bcl-2 cytoprotective phenotype could change into a 
cytodestructive phenotype following conformational change of Bcl-2, triggered by arsenic trioxide exposure. Bax 
activation might also be involved in arsenic trioxide-induced Bcl-2 conformational change. Arsenic trioxide did not 
change levels of total Bcl-2 expression, but up-regulated total Bax expression for the treatment time ranging from 3 to 
24 hours.
Conclusion: Arsenic trioxide induces apoptosis through induction of Bcl-2 conformational change, Bax activation and 
up-regulation of total Bax expression rather than affecting total Bcl-2 expression in human gastric cancer SGC7901 
cells. The conformational change of Bcl-2 may be a novel described mechanism of arsenic trioxide-induced apoptosis 
in cancer cells.
Background
Arsenic trioxide, one member of the three inorganic 
forms of arsenic, is formed by heating realgar, which is 
formed as an arsenic complex with sulfur. Although arse-
nic trioxide is highly toxic, it has been shown to have a 
therapeutic potential. It has for long been used as a drug 
in traditional Chinese medicine to treat a variety of dis-
eases, including malaria, psoriasis, syphilis, rheumatosis 
and cancer [1-3]. Contemporary studies show that arse-
nic trioxide is an effective therapeutic agent for the treat-
ment of various hematological malignancies and 
especially acute promyelocytic leukemia [4-7]. More 
recent experimental data have demonstrated that arsenic 
trioxide may have effects in the treatment of several other 
malignancies in the experimental setting, including gas-
tric cancer, lung cancer, breast cancer, hepatocellular car-
cinoma, gallbladder carcinoma, and neuroblastoma [8-
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different cellular and physiological pathways. The mecha-
nisms of action of arsenic trioxide related to the induc-
tion of apoptosis in cancer cells remain controversial. 
Arsenic trioxide affects the activities of Akt, JNK kinases, 
NF-κB, glutathione, calcium signaling, ROS, Caspases, as 
well as pro- and anti-apoptotic proteins [14-17]. Down-
regulation of Bcl-2, an "anti-apoptotic" protein, has also 
been considered as one of its significant mechanism of 
action [12,18-20].
Bcl-2 is considered as an important anti-apoptotic mem-
ber of the Bcl-2 family, its expression manifests either 
cytoprotective or cytodestructive phenotypes, depending 
on the cellular context [21]. The anti-apoptotic Bcl-2 
family members Bcl-2 and Bcl-XL have hydrophobic 
properties on their surfaces, essential for their anti-apop-
totic effect, whereas their BH3 domains are buried. In 
contrast, pro-apoptotic Bcl-2 family members have an 
exposed BH3 domain, which binds to the hydrophobic 
pockets of anti-apoptotic Bcl-2 members to inhibit their 
survival effect [22]. Subsequent research showed that the 
dual phenotypes of Bcl-2 are controlled by its protein 
conformation [23]. When the loop of Bcl-2 interacts with 
an external factor, the hydrophobic binding groove of 
Bcl-2 undergoes a large-scale realignment, resulting in 
exposure of its BH3 domain [23,24]. This conformational 
change is responsible for the conversion of Bcl-2 from a 
cytoprotective to a cytodestructive molecule.
The present study aimed at determining whether arsenic 
trioxide inhibits proliferation and induces apoptosis in 
SGC7901 human gastric cancer cells, accompanied by 




Arsenic trioxide was purchased from Sigma. A 5 mM 
stock solution of arsenic trioxide was obtained by dissolv-
ing arsenic trioxide in 1.65 M NaOH and by diluting in 
PBS, followed by adjustment of the pH to 7.0. RPMI 
Medium1640 and FBS were purchased from Invitrogen. 
Ant-Bcl-2 antibody (sc-492), anti-Bcl-2 antibody (sc-
7382), anti-Bax antibody (sc-7480), ant-Bax (6A7) anti-
body (sc-23959) and anti-β-actin antibody (sc-47778) 
were from Santa Cruz Biotechnology. Anti-Bcl-2 BH3 
(AP1303a) was from Abgent. Goat anti-mouse and rabbit 
secondary antibody conjugated to horseradish peroxidase 
(A0216, A0208), Cy3-labeled anti-rabbit IgG (A0516), 
FITC-labeled anti-mouse IgG (A0568) and DAPI were 
purchased from Beyotime Institute of Biotechnology.
Cell culture and treatment
SGC7901 human gastric cancer cells were purchased 
from Shanghai Institutes for Biological Sciences and cul-
tured in RPMI Medium1640 containing 10% FBS in a 
humidified atmosphere containing 5% CO2 at 37°C. Cells 
were split every 2-3 days by trypsinization and centrifu-
gation, followed by aspiration of the culture medium. 
Before arsenic trioxide exposure, cell density was 
adjusted to 1.5 × 104 cells per square centimeter.
Proliferation Analysis
Proliferation was measured by using the Cell Counting 
Assay Kit-8 (Dojindo Molecular Technologies) according 
to the manufacturer's protocol. One hundred microliters 
of SGC7901 human gastric cancer cells were plated on 
96-well plates at a density of 1.5 × 104 cells per square 
centimeter and cultured for 24 hours. Cells were starved 
for 24 hours by replacing the media with serum-free 
media containing 0.1% BSA, followed by exposure to dif-
ferent concentrations of arsenic trioxide (0 μmol/L, 5 
μmol/L, 10 μmol/L, 15 μmol/L and 20 μmol/L) for 24 and 
48 hours. Ten microliters of Cell Counting Assay Kit-8 
solution was added to each well, the cells were incubated 
for another 2 hours, and the absorbance at 450 nm was 
measured by using a microplate reader (BioTek Instru-
ments). The amount of the formazan dye, generated by 
the activities of dehydrogenases in cells, is directly pro-
portional to the number of living cells. Inhibitory rate of 
cellular growth was calculated as the following formula: 
Inhibitory rate (%) = (1-A value in experimental group/A 
value in control group) × 100%. The 0 μmol/L group was 
used as black control group. The IC50 value (the concen-
tration of the drug which is capable of bringing about 50% 
inhibition of cell survival) of the drug used for treatment 
was determined by plotting a graph with inhibitory rate 
of cell growth (Y-axis) against the concentrations of the 
arsenic trioxide (X-axis).
Analysis of nuclear morphology by DAPI staining
Cells grew in 6 well plates at a seeding density of 1.5 × 104 
cells per square centimeter and were then treated with 10 
μmol/L arsenic trioxide in complete media for 24 hours. 
Cells were fixed with 4% paraformaldehyde prior to 
washing with PBS. Washed cells were then stained with 1 
μg/ml DAPI for 15 min in the dark. Slides were viewed 
with a fluorescent microscope at 340-380 nm and ×1000 
magnification (Carl Zeiss). Cells were evaluated as nor-
mal or apoptotic depending on morphological character-
istics. Normal nuclei (smooth nuclear) and apoptotic 
nuclei (condensed or fragmented chromatin) were easily 
distinguished. Thus, analysis of nuclear morphology was 
observed in three independent experiments.
Apoptosis Analysis
Cells treated with different concentrations of arsenic tri-
oxide (0 μmol/L, 5 μmol/L, 10 μmol/L, 15 μmol/L, 20 
μmol/L, 25 μmol/L and 30 μmol/L) in serum-free 
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Annexin V/propidium iodide (PI) using Vybrant apopto-
sis assay kit No. 2 (Molecular Probes) and analyzed by 
flow cytometry. The 0 μmol/L group was used as black 
control group.
Immunofluorescence microscopy
Cells treated with 15 μmol/L arsenic trioxide for 12 hours 
were cultured in serum-free medium overnight on glass 
coverslips. The cells were fixed in 4% paraformaldehyde 
in PBS for 15 min and washed twice with PBS. The cells 
were then permeabilized with 1% Triton X-100 in PBS for 
5 min. Fixed cells were preincubated for 45 min in PBS 
containing 5% bovine serum albumin at room tempera-
ture, followed by incubation with various primary anti-
bodies at 4°C overnight and detected by Cy3-labeled anti-
rabbit IgG (1:300) or FITC-labeled anti-mouse IgG 
(1:300) at room temperature for 2 hours. Cells were 
stained with 1 μg/ml DAPI to visualize the nuclei. The 
images were taken under a fluorescent microscope. The 
primary antibodies included ant-Bcl-2 antibody (sc-492) 
(Santa Cruz, 1:200), anti-Bcl-2 BH3 antibody (Abgent, 
1:200) and anti-Bax(6A7) antibody (sc-23959) (Santa 
Cruz, 1:200).
Protein extraction and western blot analysis
Cells were treated with 15 μmol/L arsenic trioxide for dif-
ferent time. Both adherent and floating cells were har-
vested and lysed with Mammalian Protein Extraction 
Reagent (Pierce) according to the manufacturer's proto-
col. Equal amounts of protein were separated by SDS-
PAGE or Native-PAGE, and then transferred onto a 
PVDF membrane (Millipore). The membrane was 
blocked for 1 hour in a non-fat dried milk solution con-
taining 1% Tween-20. The membrane was then incubated 
with various primary antibodies overnight at 4°C, fol-
lowed by incubation with anti-mouse (1:5.000) secondary 
antibodies for 1 hour. Finally, protein bands were 
detected by using the Chemiluminescent Substrate (HRP) 
Kit from Pierce. The dilutions of the primary antibodies 
were anti-Bcl-2 antibody (sc-7382) in 1:800, anti-Bax 
antibody (sc-7480) in 1:800, anti-Bcl-2 BH3 antibody in 
1:500, anti-Bax (6A7) antibody in 1:500. The blots were 
reprobed with anti-β-actin antibody for loading control.
Statistical analysis
The results of each series of experiments (performed in 
triplicates) were expressed as the mean values ± standard 
deviation of the mean (SD). Statistical significance of dif-
ferences between groups was analyzed by using ANOVA 
analysis. P < 0.05 was considered statistically significant.
Results
Proliferation Analysis
SGC7901 cells were treated with different concentrations 
of arsenic trioxide (5 μmol/L, 10 μmol/L, 15 μmol/L and 
20 μmol/L) at 24 and 48 hours. The inhibitory rates of cell 
growth were 16.50 ± 0.55%, 50.83 ± 0.75%, 65.50 ± 1.05%, 
73.50 ± 1.05%; 41.83 ± 0.75%, 61.67 ± 0.82%, 71.17 ± 
0.75%, 76.67 ± 0.82%, respectively. By using curve fitting, 
the IC50 was about 10 μmol/L for 24 hours. Arsenic tri-
oxide obviously could inhibit the proliferation of 
SGC7901 cells in concentration and time-dependent 
manner (Fig. 1A).
Morphologic characteristic of apoptosis
Nuclear morphology analysis showed characteristic 
apoptotic changes, such as convoluted nuclei with cavita-
tions, clumps of chromatin abutting to inner regions of 
the nuclear envelope between the nuclear pores, break-
down of nuclear envelope, chromatin condensation and 
dissociation of DNA fragments in SGC7901 cells after 
treatment with arsenic trioxide for 24 hours (Fig. 2A).
Apoptosis Analysis
SGC7901 cells were treated with different concentrations 
of arsenic trioxide (0 μmol/L, 5 μmol/L, 10 μmol/L, 15 
μmol/L, 20 μmol/L, 25 μmol/L and 30 μmol/L) for 24 
hours. The early and late apoptosis/necrosis rates were 
11.49 ± 0.63%, 2.28 ± 1.46%, 3.97 ± 1.28%, 16.94 ± 3.42%, 
21.50 ± 4.51%, 19.16 ± 4.21%, 21.53 ± 4.16%; 3.52 ± 0.49%, 
4.21 ± 0.48%, 4.42 ± 1.12%, 7.92 ± 0.61%, 23.02 ± 1.46%, 
26.80 ± 1.86%, 19.39 ± 1.23%, respectively, which sug-
gested that arsenic trioxide induce apoptosis (Fig. 1B).
Arsenic trioxide induced Bcl-2 conformational change and 
Bax activation
SGC7901 cells were strongly stained by anti-Bcl-2 N ter-
minus antibody. It showed that SGC7901 cells highly 
expressed total Bcl-2 protein (Fig. 2B). Moreover, an 
enhanced immunostaining by anti-Bcl-2 BH3 antibody, 
as compared to the "black control group" (0 hour), was 
observed in SGC7901 cells treated with 15 μmol/L arse-
nic trioxide for 12 hours using immunofluorescence. The 
black control group (0 hour) did not immunostain by the 
anti-Bax (6A7) antibody, suggesting that Bax was inactive 
in the cells. However, SGC7901 cells treated with 15 
μmol/L arsenic trioxide displayed strong immunostaining 
with the anti-Bax (6A7) antibody, demonstrating that 
arsenic trioxide could activate Bax (Fig. 2C). After treat-
ment of 15 μmol/L arsenic trioxide for the indicated 
times (0 hour, 3 hours, 6 hours, 12 hours and 24 hours), 
Western blot showed that the expression of BH3 domain 
exposed Bcl-2 had an upward trend and reached a peak at 
12 hours and the difference as compared with 0 hour was 
statistically significant (P < 0.05). By time, the activated 
Bax also presented an upward trend and reached a peak 
Zheng et al. World Journal of Surgical Oncology 2010, 8:31
http://www.wjso.com/content/8/1/31
Page 4 of 9at 24 hours and the difference compared to 0 hour was 
statistically significant (P < 0.05) (Fig. 3A). Arsenic triox-
ide-treated SGC7901 cells, detected by western blot and 
stained by both anti-Bcl-2 (BH3) and anti-Bax (6A7) anti-
bodies, express conformational change of Bcl-2, which 
may play a role in arsenic trioxide-induced apoptosis and 
Bax activation.
Arsenic trioxide did not affect total Bcl-2 expression, but 
up-regulated total Bax expression
After 15 μmol/L arsenic trioxide exposure for various 
times (0 hour, 3 hours, 6 hours, 12 hours and 24 hours), 
the change in total Bcl-2 expression was unconspiciuous 
and the differences compared to the different groups did 
not statistically differ (P > 0.05). Total Bax had a higher 
expression and reached a peak at 3 hours and the differ-
ences compared to 0 hour was statistically significant (P < 
0.05), though the levels descended at 3 hours (Fig. 3B). 
The results showed that arsenic trioxide did not cause 
any apparent change in levels of Bcl-2, but Bax expression 
was up-regulated for treatment times ranging from 3 to 
24 hours.
Discussion
Arsenic is a well-known environmental toxic and carci-
nogenic substance, and an effective chemotherapeutic 
drug. Due to the dual capability of arsenic, the agent car-
ries significant risks for medical applications. The under-
lying mechanisms are, however, not fully understood. 
Arsenic exerts its effect by inhibiting the activities of sev-
eral enzymes, especially those involved in cellular signal-
ing pathways and DNA synthesis and repair. During the 
past centuries, a number of arsenic compounds have 
Figure 1 A. Inhibitory effects of arsenic trioxide on SGC7901 cell. B The effects of arsenic trioxide on early and late apoptosis/necrosis of SGC7901 
cell. (* represents p < 0.05 compared to the black control group and arsenic trioxide treated groups).
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arsenicals, has been used in a variety of ways over the 
past hundred years, but most commonly in the treatment 
of malignancies. Owing to the impressive effects of arse-
nic trioxide in hematological cancers and solid tumor 
cells in vitro, the mechanisms of arsenic trioxide-medi-
ated cell death have recently come under increasing scru-
tiny. Arsenic trioxide may be a promising candidate for 
the treatment of other malignancies. The combination 
therapy of arsenic trioxide and other chemotherapeutic 
agents have been applied experimentally for treatment of 
refractory malignant tumors.
In the current study, we observed that arsenic trioxide 
had a strong anti-proliferative effect, most likely by 
induction of apoptosis, on human gastric cancer 
SGC7901 cells in a dose and time dependent manner. As 
has previously been reported, the cellular and biochemi-
cal effects of arsenic were performed using concentra-
tions greater than 5 μmol/L, often 50 μmol/L, and the 
50% inhibitory concentration (IC50) of arsenic trioxide 
on proliferation of SGC7901 cells was about 10 μmol/L 
for 24 hours. Maybe it was much too high than relevant 
to therapeutic levels (1 to 2 μmol/L) [25,26]. However, 
from the 24 and 48 hours curve fitting, we could suppose 
that the 50% inhibitory concentration (IC50) for 72 hours 
may be similar to clinically therapeutic levels, which also 
has been described by others [8,9,27]. This suggests that 
Figure 2 A. Nuclear morphologic changes showing features of apoptosis in SGC7901 cells after treatment with arsenic trioxide for 24 
hours. (a) Untreated SGC7901 cells; (b-f) 15 μmol/L arsenic trioxide-treated SGC7901 cells. The cells were stained using DAPI staining. B. Untreated 
SGC7901 cells stained by anti-Bcl-2 N terminus antibody. C SGC7901 cell stained by anti-Bcl-2 BH3 and anti-Bax(6A7) antibody before and after expo-
sure to 15 μmol/L arsenic trioxide for 12 hours.
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nic trioxide.
The mechanisms of arsenic trioxide-induced anti-prolif-
eration have been extensively investigated. Apoptosis 
appears to be the main phenomenon resulting in signifi-
cant cell death and cell growth inhibition. Arsenic triox-
ide is known to modulate multiple signal transduction 
pathways, including inhibition of telomerase activity, 
induction of reactive oxygen species release, and inhibi-
tion of survival pathways involving extracellular signal 
regulated kinase, Akt, calcium signaling and NF-κB activ-
ities [14-17,28]. Interestingly, the apoptotic effect of arse-
nic trioxide largely depends on a Bcl-2-controlled 
pathway [12,18-20].
Bcl-2, an anti-apoptotic Bcl-2 family member, for which 
an increased expression has been associated with a more 
aggressive malignant phenotype and drug resistance to 
various categories of chemotherapeutic drugs in malig-
nancies. Small molecule inhibitors of the Bcl-2 family 
proteins, designed to bind the hydrophobic groove of 
Figure 3 A. The expression of BH3 exposed Bcl-2 and activated Bax after exposed to 15 μmol/L arsenic trioxide in SGC7901 cell. B The ex-
pression of total Bcl-2 and total Bax after exposure to 15 μmol/L arsenic trioxide in SGC7901 cell. (* represents p < 0.05 between black control group 
and arsenic trioxide treated groups).
Zheng et al. World Journal of Surgical Oncology 2010, 8:31
http://www.wjso.com/content/8/1/31
Page 7 of 9anti-apoptotic Bcl-2 proteins in place of BH3-only pro-
teins, are potential agents to treat cancers. They can oli-
gomerize Bax or Bak, which subsequently depolarize in 
the mitochondrial membrane potential to release cyto-
chrome c and induce apoptosis [29]. Agents targeting 
anti-apoptotic Bcl-2 family members have preclinical 
activity as single agents and also affect combination with 
other anti-neoplastic agents. Recent researches have 
demonstrated that Bcl-2 could manifest opposing pheno-
types, induced by interactions with proteins, such as 
Nur77, suggesting novel strategies for regulating apopto-
sis in cancers and other diseases [30]. This phenotype 
change of Bcl-2 is controlled by its protein conforma-
tional change. When the loop of Bcl-2 interacts with an 
external factor, the hydrophobic binding groove of Bcl-2 
undergoes a large-scale realignment, resulting in expo-
sure of its BH3 domain [21,22]. It was also reported that 
paclitaxel could directly target Bcl-2 in the loop domain, 
mimics activity of Nur77, thereby facilitating the initia-
tion of apoptosis [31].
Whether Bcl-2 phenotype changes phenomenon occur in 
arsenic trioxide-induced cell apoptosis is still unknown. 
In the present study, we used anti-Bcl-2 BH3 antibody to 
detect the conformational change of Bcl-2. When Bcl-2 
undergoes conformational change, the hydrophobic bind-
ing groove of Bcl-2 gives rise to a large-scale realignment, 
resulting in exposure of its cryptic BH3 domain and can 
be recognized by Bcl-2 BH3 antibody. We used Bax (6A7) 
antibody to detect the activated Bax, Bax undergoes a 
conformational change and oligomerization during early 
apoptosis, which can be followed by exposure of cryptic 
antibody epitopes (the N-terminal residues 1-21). This 
type of Bax can be recognized by anti-Bax (6A7) anti-
body. The novel finding from this work was that 
SGC7901 cells highly expressed Bcl-2, but they were 
weakly stained by the anti-Bcl-2 BH3 antibody, suggest-
ing that there were two Bcl-2 phenotypes coexisting in 
SGC7901 cells and mostly Bcl-2 was anti-apoptotic. The 
results showed that Bcl-2 anti-apoptotic phenotype could 
change into a pro-apoptotic phenotype following expo-
sure to arsenic trioxide. Also Bax activation was involved 
in arsenic trioxide-induced conformational change of 
Bcl-2 by immunostaining SGC7901 cells with anti-Bax 
(6A7) antibody that recognizes activated Bax. Arsenic tri-
oxide caused no apparent change in the levels of Bcl-2, 
but up-regulated Bax for treatment times ranging from 3 
to 24 hours. Thus, Bcl-2 conformational change, Bax acti-
vation and up-regulation of total Bax expression involved 
arsenic trioxide-induced apoptosis rather than affecting 
total Bcl-2 expression in human gastric cancer SGC7901 
cells.
Although the anti-apoptotic effect of Bcl-2 is well estab-
lished, the role of Bcl-2 in cancer response to therapy and 
drug resistance has not been completely explored. The 
mechanism how it promotes cell death has recently 
gained increasing interest. In general, over-expression 
and up-regulation of Bcl-2 has been associated with resis-
tance to chemotherapy in various human cancers [29,32], 
and many studies have shown that over-expression of 
Bcl-2 is a poor prognostic factor in various cancers. It was 
found that Bcl-2 expression tended to be associated with 
a worsened survival in olfactory neuroblastoma (ONB) 
[33]. Also the expression of Bcl-2 and Bax proteins, evalu-
ated by immunohistochemical staining in specimens 
from 110 patients with oral squamous cell carcinoma 
(OSCC) showed that the 5-year survival rate was signifi-
cantly higher in patients with a ratio of Bcl-2/Bax ≤ 1 as 
compared to those with Bcl-2/Bax > 1 [34]. On the oppo-
site side, high Bcl-2 expression also correlated with favor-
able parameters and a better prognosis in other cancers. 
A recent systematic review of the literature showed that 
over-expression of Bcl-2 was a good prognostic factor for 
survival in patients with non-small cell lung cancer [35]. 
Bcl-2 expression also correlated with a favorable progno-
sis in colorectal cancer [36], and with improved overall 
survival rate in oral squamous cell carcinoma [37].
Our finding of conformational change of Bcl-2 in 
SGC7901 cells following exposure to arsenic trioxide is 
important for founding an explanation accounting for the 
opposing biological activities of Bcl-2. This may also rep-
resent that arsenic trioxide may be a promising candidate 
for the future treatment of malignancies that over-
express endogenous Bcl-2, though substantial experi-
mental and clinical research remains to validate its poten-
tial value.
Conclusion
Our results show that arsenic trioxide is an effective anti-
cancer agent with potential for human gastric cancer. 
Arsenic trioxide can reduce proliferation and induce 
apoptosis in SGC7901 human gastric cancer cells. There 
are two Bcl-2 phenotypes coexisting in SGC7901 cells 
and the Bcl-2 cytoprotective phenotype can change into a 
cytodestructive phenotype following arsenic trioxide 
exposure. Also Bax activation is involved in arsenic triox-
ide-induced conformational change of Bcl-2 in SGC7901 
cells. The conformational change of Bcl-2 may be the new 
mechanism explaining arsenic trioxide-induced apopto-
sis, other than the ones affecting the total Bcl-2 expres-
sion in some cancer cells.
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